Evidence map›Paper›PMID 41836677›Full record

Trial reportCancer communications (London, England)2026

IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort.

Javier Martin-Broto, Sandra J Strauss, Emanuela Palmerini, Claudia Valverde, Ana Sebio, Andres Redondo, Silvia Stacchiotti, Giovanni Grignani, Sandra Aliberti, Roberto Diaz-Beveridge and 18 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer communications (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Javier Martin-BrotoDepartment of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.ORCID https://orcid.org/0000-0001-7350-6916
Sandra J StraussDepartment of Medical Oncology, University College London Hospital, London, UK.
Emanuela PalmeriniDepartment of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Ortopedico Rizzoli, Bologna, Italy.
Claudia ValverdeDepartment of Medical Oncology, University Hospital Vall d'Hebron, Barcelona, Spain.
Ana SebioDepartment of Medical Oncology, Sant Pau Hospital, Barcelona, Spain.
Andres RedondoDepartment of Medical Oncology, University Hospital La Paz, Madrid, Spain.
Silvia StacchiottiMedical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy.
Giovanni GrignaniMedical Oncology Department, Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia-Istituto di Ricovero e Cura a Carattere Scientifico (FPO-IRCCS), Candiolo, Italy.
Sandra AlibertiMedical Oncology Department, Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia-Istituto di Ricovero e Cura a Carattere Scientifico (FPO-IRCCS), Candiolo, Italy.
Roberto Diaz-BeveridgeDepartment of Medical Oncology, University Hospital La Fe, Valencia, Spain.
Enrique Gonzalez BillalabeitiaDepartment of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain.
Josefina CruzDepartment of Medical Oncology, Canarias University Hospital, La Laguna, Spain.
Irene Carrasco-GarciaDepartment of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain.
Toni IbrahimDepartment of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Ortopedico Rizzoli, Bologna, Italy.
Juan Diaz-MartinInstitute of Biomedicine of Seville, Spanish National Research Council-University of Seville, Department of Pathology, University Hospital Virgen del Rocio, Seville, Spain.
Carmen Salguero-ArandaInstitute of Biomedicine of Seville, Spanish National Research Council-University of Seville, Department of Pathology, University Hospital Virgen del Rocio, Seville, Spain.
Antonio GutierrezDepartment of Hematology, University Hospital Son Espases, Palma de Mallorca, Spain.
Empar Mayordomo-ArandaDepartment of Pathology, University Hospital La Fe, Valencia, Spain.
Rafael RamosDepartment of Pathology, University Hospital Son Espases, Palma de Mallorca, Spain.
Jose MerinoDepartment of Pathology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Paola ColliniAdvanced Diagnostic Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.
Roberto TiraboscoDepartment of Pathology, University College London Hospital, London, UK.
Silvia BagueDepartment of Pathology, Sant Pau Hospital, Barcelona, Spain.
Cleofe RomagosaDepartment of Pathology, University Hospital Vall d'Hebron, Barcelona, Spain.
Maria Augusta CarreraUniversity Hospital General de Villalba, Madrid, Spain.
Patricio LedesmaSofpromed Investigación Clínica, Palma de Mallorca, Spain.
Nadia HindiDepartment of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
David Silva MouraUniversity Hospital General de Villalba, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsNivolumabSarcoma, Clear CellSunitinibAdolescentAdultAgedAged, 80 and overChildFemaleHumansMaleMiddle AgedProgression-Free SurvivalRNA-Binding Protein EWSNivolumabRNA-Binding Protein EWSSunitinib

Identifiers

PMID41836677
PMCPMC12981246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.